A central challenge in cancer therapy is the effective delivery of anticancer treatments while minimizing adverse effects on patient health. The potential dual impact of therapy is clearly illustrated in cancer-associated cachexia, a multifactorial syndrome characterized by involuntary weight loss,...
Patients with sarcopenia and elevated body mass index (BMI) are at high risk of platinum-associated adverse events (AEs). This study examines the association between sarcopenia, BMI, and AEs in patients with non-small cell lung cancer (NSCLC). This retrospective cohort study...
Sarcopenia is an important prognostic factor for cancer patients. Here, we prospectively examined the effects of sarcopenia on progression-free survival (PFS) and overall survival (OS) of patients with pancreatic ductal adenocarcinoma (PDAC) treated with first-line gemcitabine and nab-paclitaxel (GnP). This...
In cancer cachexia, cytokine release by tumours causes weight loss, decreased therapeutic efficacy, and worsened prognosis. Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) and fibroblast inducible factor 14 (Fn14) are cancer cachexia-related proteins; however, their expression in oesophageal squamous...
Cachexia is a syndrome in patients with cancer that reduces life quality and prognosis, characterized by severe weight loss, muscle atrophy, and anorexia. How cachexia adversely affects older patients with small cell lung cancer (SCLC) remains uncertain. This study aimed...
Glutamatergic neurons of external lateral parabrachial nucleus co-expressing calcitonin gene related peptide (elPB CGRP) negatively regulate food intake and establish food aversive memories. They also promote malaise-dependent anorexia, sickness behavior and tumor cachexia. In spite of the pathogenetic potential of...
Anticancer chemotherapy is an underappreciated contributor to cancer cachexia, an often-irreversible body-wasting condition that causes 20%-30% of cancer-related deaths. An obstacle to predicting, monitoring and understanding the mechanisms underlying chemotherapy cachexia is that each cancer (and subtype) is assigned different...
Visceral obesity (VO), associated with excessive visceral adipose tissue (VAT), has been extensively studied in cancer. However, whether low VAT can predict the prognosis of colorectal liver metastases (CRLM) undergoing neoadjuvant chemotherapy (NAC) remains unknown. This multicentre real-world cohort study...
This retrospective, multicenter cohort study aimed to determine whether cancer cachexia serves as a biomarker for determining the most effective treatment for patients having non-small-cell lung cancer (NSCLC) with high programmed death ligand 1 (PD-L1) expression treated with immune checkpoint...
Patients with borderline resectable (BR) or locally advanced pancreatic cancer (LAPC) require complex management strategies. This study evaluated the prognostic significance of the perichemotherapy skeletal muscle index (SMI) and carbohydrate antigen 19-9 (CA 19-9) in patients with BRPC or LAPC...
Cancer cachexia complicates advanced non-small cell lung cancer (NSCLC); however, it remains unclear how often cachexia occurs and how it affects the course of chemotherapy in patients receiving first-line systemic therapy. We conducted a multicentre, prospective observational study and enrolled...
The primary objective of this study was to assess the frequency of body composition increases and their relationships to changes in body weight in two cohorts of real world, treatment-naรฏve, advanced non-small cell lung cancer (NSCLC) patients. One cohort received...
The decline of physical function during chemotherapy predicts poor quality of life and premature death. It is unknown if resistance training prevents physical function decline during chemotherapy in colon cancer survivors. This multicenter trial randomly assigned 181 colon cancer survivors...
This comprehensive review sheds light on cancer cachexia (CC), a significant condition marked by muscle wasting in cancer patients, emphasizing its molecular mechanisms and potential treatments. Highlighting the challenge CC presents, especially in older individuals, the article discusses the multifaceted approach needed to combat this syndrome.
